
#### D-1. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), BMI Percentile, 3-11 Years









Comagine Health

D-1.


Appendix D

#### D-2. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), BMI Percentile, 12-17 Years










#### D-3. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), BMI Percentile, Total










#### D-4. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Nutrition Counseling, 3-11 Years










\*\*\* Data suppressed due to small sample size.

#### D-5. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Nutrition Counseling, 12-17 Years










## D-6. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Nutrition Counseling, Total










\*\*\* Data suppressed due to small sample size.

# D-7. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Physical Activity Counseling, 3-11 Years










Appendix D


\* \* \* Data suppressed due to small sample size.

D-8. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Physical Activity Counseling, 12-17










#### D-9. Weight Assessment and Counseling for Nutrition and Physical Activity for Children & Adolescents (WCC), Physical Activity Counseling, Total










\* \* \* Data suppressed due to small sample size.

## D-10. Childhood Immunization Status (CIS), DTaP










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-11. Childhood Immunization Status (CIS), IPV










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-12. Childhood Immunization Status (CIS), MMR










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-13. Childhood Immunization Status (CIS), HIB











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-14. Childhood Immunization Status (CIS), Hepatitis B










## D-15. Childhood Immunization Status (CIS), VZV










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-16. Childhood Immunization Status (CIS), Pneumococcal











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-17. Childhood Immunization Status (CIS), Hepatitis A










## D-18. Childhood Immunization Status (CIS), Rotavirus











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-19. Childhood Immunization Status (CIS), Influenza






## D-20. Childhood Immunization Status (CIS), Combo 3










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-21. Childhood Immunization Status (CIS), Combo 7










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-22. Childhood Immunization Status (CIS), Combo 10


Not Reported





<30 Patients






<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-23. Childhood Immunization Status (CIS-E), DTaP











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-24. Childhood Immunization Status (CIS-E), IPV











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-25. Childhood Immunization Status (CIS-E), MMR










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-26. Childhood Immunization Status (CIS-E), HIB











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-27. Childhood Immunization Status (CIS-E), Hepatitis B











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-28. Childhood Immunization Status (CIS-E), VZV










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-29. Childhood Immunization Status (CIS-E), Pneumococcal











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-30. Childhood Immunization Status (CIS-E), Hepatitis A











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-31. Childhood Immunization Status (CIS-E), Rotavirus











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-32. Childhood Immunization Status (CIS-E), Influenza











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-33. Childhood Immunization Status (CIS-E), Combo 3










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-34. Childhood Immunization Status (CIS-E), Combo 7











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-35. Childhood Immunization Status (CIS-E), Combo 10










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-36. Immunizations for Adolescents (IMA), Meningococcal










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-37. Immunizations for Adolescents (IMA), Tdap









<sup>\* \* \*</sup> Data suppressed due to small sample size.

D-37.

Comagine Health


Appendix D

### D-38. Immunizations for Adolescents (IMA), HPV










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-39. Immunizations for Adolescents (IMA), Combo 1










\* \* \* Data suppressed due to small sample size.

### D-40. Immunizations for Adolescents (IMA), Combo 2










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-41. Immunizations for Adolescents (IMA-E), Meningococcal











<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-42. Immunizations for Adolescents (IMA-E), Tdap











<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-43. Immunizations for Adolescents (IMA-E), HPV










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-44. Immunizations for Adolescents (IMA-E), Combo 1










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-45. Immunizations for Adolescents (IMA-E), Combo 2










\* \* \* Data suppressed due to small sample size.

#### D-46. Lead Screening in Children (LSC)










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-47. Breast Cancer Screening (BCS)







42.3% 4,072

Great

**Rivers** 

Bar Chart Legend:				
Confidence Interval		tatewide Veighted Rate		National 75th Percentile

<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-48. Breast Cancer Screening (BCS-E), Total

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-49. Cervical Cancer Screening (CCS)










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-50. Colorectal Cancer Screening (COL), Age 50-75 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-51. Colorectal Cancer Screening (COL), Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-52. Colorectal Cancer Screening (COL-E), Age 50-75 Years











<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-53. Colorectal Cancer Screening (COL-E), Total











<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-54. Chlamydia Screening in Women (CHL), 16-20 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.


## D-55. Chlamydia Screening in Women (CHL), 21-24 Years

Not Reported









<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-56. Chlamydia Screening in Women (CHL), Total

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-57. Appropriate Testing for Pharyngitis (CWP), 3-17 Years

Not Reported





Bar Chart Legend:			
Confidence Interval	Statewide Weighted Rate	National 50th Percentile	National 75th Percentile




<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-58. Appropriate Testing for Pharyngitis (CWP), 18-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-59. Appropriate Testing for Pharyngitis (CWP), Total

Not Reported





Bar Chart Legend:			
Confidence	Statewide	National 50th	National 75th
Interval	Weighted Rate	Percentile	Percentile

Great Rivers		72.6% 1,320	
Greater Columbia		75.4% 4,708	
King	King County Total	72.7% 2,884	-
	Seattle	74.0% 734	-
	East King	72.4% 468	-
	South King	72.2% 1,678	
North Central		73.9% 1,101	
North Sound		74.6% 2,436	
Pierce		76.9% 2,150	-
Salish		78.3% 727	
Southwest		80.6% 1,056	
Spokane		78.2% 2,877	
Thurston - Mason		77.9% 915	
* * * Data su	ppressed due	to small sam	unle size.

<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-60. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)


<30 Patients

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-61. Pharmacotherapy Management of COPD Exacerbation (PCE), Systemic Corticosteroid









\* \* \* Data suppressed due to small sample size.

Comagine Health

D-61.


Appendix D

### D-62. Pharmacotherapy Management of COPD Exacerbation (PCE), Bronchodilator










<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-63. Asthma Medication Ratio (AMR), 5-11 Years

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-64. Asthma Medication Ratio (AMR), 12-18 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.


#### D-65. Asthma Medication Ratio (AMR), 19-50 Years

Not Reported









<sup>\* \* \*</sup> Data suppressed due to small sample size.


#### D-66. Asthma Medication Ratio (AMR), 51-64 Years

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.


#### D-67. Asthma Medication Ratio (AMR), Total

Not Reported









<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-68. Controlling High Blood Pressure (CBP)


Not Reported



<30 Patients







<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-68.


Appendix D

### D-69. Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)










\* \* \* Data suppressed due to small sample size.

#### D-70. Statin Therapy for Patients With Cardiovascular Disease (SPC), Received Statin Therapy, 21-75 Years (Male)











#### D-71. Statin Therapy for Patients With Cardiovascular Disease (SPC), Received Statin Therapy, 40-75 Years (Female)









\*\*\* Data suppressed due to small sample size.

### D-72. Statin Therapy for Patients With Cardiovascular Disease (SPC), Received Statin Therapy Total





Bar Chart Legend:			
Confidence	Statewide	National 50th	National 75th
Interval	Weighted Rate	Percentile	Percentile

Great Rivers		82.6% 379	
Greater Columbia		81.9% 519	
King	King County Total	83.6% 1,270	
	Seattle	85.3% 443	-
	East King	86.6% 172	
	South King	81.8% 653	
North Central		83.9% 224	
North Sound		84.0% 794	
Pierce		80.0% 901	
Salish		78.6% 364	-
Southwest		83.0% 353	
Spokane		80.3% 674	-
Thurston - Mason		79.2% 284	_
* * * Data su	ppressed due	to small sam	ple size.


<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-72.

Appendix D

## D-73. Statin Therapy for Patients With Cardiovascular Disease (SPC), Statin Adherence 80%, 21-75 Years (Male)



Great Rivers		72.2% 194	
Greater Columbia		73.5% 291	+
King	King County Total	73.0% 764	-
	Seattle	76.6% 291	
	East King	74.8% 111	
	South King	69.5% 361	
North Central		67.7% 130	
North Sound		72.4% 463	+
Pierce		64.7% 453	-
Salish		73.3% 187	+
Southwest		76.1% 209	
Spokane		72.0% 350	
Thurston - Mason		70.1% 154	
	ppressed due	to small sam	nle size

\* \* \* Data suppressed due to small sample size.

Comagine Health


D-73.

### D-74. Statin Therapy for Patients With Cardiovascular Disease (SPC), Statin Adherence 80%, 40-75 Years (Female)










\* \* \* Data suppressed due to small sample size.

### D-75. Statin Therapy for Patients With Cardiovascular Disease (SPC), Statin Adherence 80%, Total









<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-75.

## D-76. Cardiac Rehabilitation (CDE), Initiation, Total


Not Reported



<30 Patients








<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-76.

# D-77. Cardiac Rehabilitation (CDE), Engagement1, Total


Not Reported



<30 Patients







<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-77.

# D-78. Cardiac Rehabilitation (CDE), Engagement2, Total


Not Reported



<30 Patients







\* \* \* Data suppressed due to small sample size.

Comagine Health

D-78.

## D-79. Cardiac Rehabilitation (CDE), Achievement, Total


Not Reported





<30 Patients







Comagine Health

D-79.

### D-80. Hemoglobin A1c Control for Patients with Diabetes (HBD), Poor HbA1c Control >9% (Note that a lower score is better for this measure)






### D-81. Hemoglobin A1c Control for Patients with Diabetes (HBD), HbA1c Control < 8.0%









<sup>\* \* \*</sup> Data suppressed due to small sample size.


## D-82. Eye Exam for Patients with Diabetes (EED)

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-83. Blood Pressure Control for Patients with Diabetes (BPD)







**Bar Chart Legend:** 


Confidence
Interval

Statewide Weighted Rate National 50th Percentile

National 75th Percentile


\* \* \* Data suppressed due to small sample size.

### D-84. Kidney Health Evaluation for Patients with Diabetes (KED), 18-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-85. Kidney Health Evaluation for Patients with Diabetes (KED), 65-74 Years









\* \* \* Data suppressed due to small sample size.

## D-86. Kidney Health Evaluation for Patients with Diabetes (KED), 75-85 Years





Bar Chart Legend:			
Confidence Interval	Statewide Weighted Rate	National 50th Percentile	National 75th Percentile

Great Rivers Greater		* * * 2		
Columbia		* * * 12		
King	King County Total	49.3% 73		
	Seattle	* * * 9		
	East King	* * * 14		
	South King	50.0% 50	+	
North Central		* * *		
North Sound		46.7% 30	-	
Pierce		* * * 10		
Salish		* * *		
Southwest		* * * 9		
Spokane		* * * 17		
Thurston - Mason		* * *		


<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-87. Kidney Health Evaluation for Patients with Diabetes (KED), Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-88. Statin Therapy for Patients With Diabetes (SPD), Received Statin Therapy









<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-88.

## D-89. Statin Therapy for Patients With Diabetes (SPD), Statin Adherence 80%







Great Rivers		70.2% 1,327	-
Greater Columbia		69.5% 3,083	1-
King	King County Total	67.5% 5,291	
	Seattle	69.2% 1,771	
	East King	70.1% 579	
	South King	65.9% 2,939	-
North Central		64.1% 1,070	_
North Sound		68.8% 3,045	 
Pierce		68.9% 2,883	
Salish		69.7% 915	1
Southwest		71.8% 1,309	
Spokane		67.8% 2,035	I I
Thurston - Mason		70.5% 940	-


<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-90. Diagnosed Mental Health Disorders (DMH), 1-17 Years












<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-91. Diagnosed Mental Health Disorders (DMH), 18-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-92. Diagnosed Mental Health Disorders (DMH), 65+ Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-93. Diagnosed Mental Health Disorders (DMH), Total

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-94. Antidepressant Medication Management (AMM), Effective Acute Phase

Not Reported









<sup>\* \* \*</sup> Data suppressed due to small sample size.


### D-95. Antidepressant Medication Management (AMM), Continuation Phase

Not Reported










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-96. Follow-Up Care for Children Prescribed ADHD Medication (ADD), Initiation










\* \* \* Data suppressed due to small sample size.

### D-97. Follow-Up Care for Children Prescribed ADHD Medication (ADD), Continuation











\* \* \* Data suppressed due to small sample size.

### D-98. Follow-Up Care for Children Prescribed ADHD Medication (ADD-E), Initiation Phase










<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

### D-99. Follow-Up Care for Children Prescribed ADHD Medication (ADD-E), Continuation and Maintenance (C&M) Phase





<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022


D-99.

### D-100. Follow-Up after Hospitalization for Mental Illness (FUH), 30-Day Follow-Up, 6-17 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health


D-100.

### D-101. Follow-Up after Hospitalization for Mental Illness (FUH), 30-Day Follow-Up, 18-64 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.


Comagine Health D-101. Appendix D

### D-102. Follow-Up after Hospitalization for Mental Illness (FUH), 30-Day Follow-Up, Total









<sup>\* \* \*</sup> Data suppressed due to small sample size.


Comagine Health D-102. Appendix D

### D-103. Follow-Up after Hospitalization for Mental Illness (FUH), 7-Day Follow-Up, 6-17 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.


Comagine Health D-103. Appendix D

### D-104. Follow-Up after Hospitalization for Mental Illness (FUH), 7-Day Follow-Up, 18-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-105. Follow-Up after Hospitalization for Mental Illness (FUH), 7-Day Follow-Up, Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.


Comagine Health

D-105.


### D-106. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 30-Day Follow-Up, 6-17 Years




D-106.



## D-107. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 30-Day Follow-Up, 18-64 Years




### D-108. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 30-Day Follow-Up, Total










\* \* \* Data suppressed due to small sample size.

### D-109. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 7-Day Follow-Up, 6-17 Years











### D-110. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 7-Day Follow-Up, 18-64 Years






### D-111. Follow-Up After Emergency Department Visit for Mental Illness (FUM), 7-Day Follow-Up, Total









<sup>\* \* \*</sup> Data suppressed due to small sample size.


Comagine Health D-111. Appendix D

### D-112. Diagnosed Substance Use Disorders (DSU), Any Substance Use Disorder, 13-17 years










### D-113. Diagnosed Substance Use Disorders (DSU), Any Substance Use Disorder, 18-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-114. Diagnosed Substance Use Disorders (DSU), Any Substance Use Disorder, 65+ Years










# D-115. Diagnosed Substance Use Disorders (DSU), Any Substance Use Disorder, Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-116. Follow-Up After Emergency Department Visit for Substance Use (FUA), 30-Day Follow-Up, 13-17 Years






### D-117. Follow-Up After Emergency Department Visit for Substance Use (FUA), 30-Day Follow-Up, 18+ Years












D-118. Follow-Up After Emergency Department Visit for Substance Use (FUA), 30-Day Follow-Up, Total




### D-119. Follow-Up After Emergency Department Visit for Substance Use (FUA), 7-Day Follow-Up, 13-17 Years





### D-120. Follow-Up After Emergency Department Visit for Substance Use (FUA), 7-Day Follow-Up, 18+ Years

**Greater Columbia** 




King

Pierce

Southwest


Thurston - Mason

**Great Rivers** 






# D-121. Follow-Up After Emergency Department Visit for Substance Use (FUA), 7-Day Follow-Up, Total












<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-122. Follow-Up After High Intensity Care for Substance Use Disorder (FUI), 30-Day Follow-Up, 18-64 Years




### D-123. Follow-Up After High Intensity Care for Substance Use Disorder (FUI), 30-Day Follow-Up, Total






### D-124. Follow-Up After High Intensity Care for Substance Use Disorder (FUI), 7-Day Follow-Up, 18-64 Years





### D-125. Follow-Up After High Intensity Care for Substance Use Disorder (FUI), 7-Day Follow-Up, Total






# D-126. Pharmacotherapy for Opioid Use Disorder (POD), 16-64 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-127. Pharmacotherapy for Opioid Use Disorder (POD), Total


Not Reported



<30 Patients








<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-128. Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)



Great Rivers		76.6% 1,122	_
Greater Columbia		76.0% 1,805	-
King	King County Total	78.6% 3,522	
	Seattle	77.4% 1,766	_
	East King	79.0% 420	-
	South King	79.9% 1,335	
North Central		81.7% 573	
North Sound		79.7% 2,496	
Pierce		80.7% 1,942	
Salish		80.0% 931	
Southwest		76.3% 1,205	_
Spokane		80.0% 2,080	
Thurston - Mason		76.9% 910	_
* * * Data su	ppressed due	to small sam	ple size.

Interval

Weighted Rate

Percentile


Percentile

D-128.

Comagine Health


Appendix D

### D-129. Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)









# D-130. Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)




	* * *		
	9		
	***		
	6		i i
	O		
King	E4.40/		
		_	
	37		
. Otal			
Coottle	* * *		- I i
Seattle	18		
	* * *		i i
East King	2		
	_		
	***		
South King	17		
	17		
	* * *		- I i
	20		i i
			+
	27		- i
			+
	* * *		
	7		
			-
	* * *		i i
	7		
	* * *		
	15		
	***		
	2		
	King County Total Seattle East King South King	# * * * * 6  King County 37 Total	9  *** 6  King County Total  ***  Seattle  18  East King  2  South King  17  ***  ***  20  ***  ***  7  ***  ***

### D-131. Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)











<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health D-131. Appendix D

# D-132. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose Testing, 1-11 Years






Comagine Health D-132. Appendix D

### D-133. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose Testing, 12-17 Years










# D-134. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose Testing, Total












### D-135. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Cholesterol Testing, 1-11 Years







Comagine Health D-135. Appendix D

### D-136. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Cholesterol Testing, 12-17 Years






### D-137. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Cholesterol Testing, Total











### D-138. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose and Cholesterol Testing, 1-11 Years











### D-139. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose and Cholesterol Testing, 12-17 Years










### D-140. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM), Blood Glucose and Cholesterol Testing, Total











### D-141. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose Testing, 1-11 Years






There are no national benchmarks reported for this measure in MY2022

### D-142. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose Testing, 12-17 Years











<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

### D-143. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose Testing, Total





<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

Interval

Weighted Rate

Percentile


Percentile


D-143.

Comagine Health

Appendix D

### D-144. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Cholesterol Testing, 1-11 Years






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

D-144.

#### D-145. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Cholesterol Testing, 12-17 Years






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

#### D-146. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Cholesterol Testing, Total






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

#### D-147. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose and Cholesterol Testing, 1-11 Years






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

#### D-148. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose and Cholesterol Testing, 12-17 Years






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

#### D-149. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E), Blood Glucose and Cholesterol Testing, Total






<sup>\* \* \*</sup> Data suppressed due to small sample size.


There are no national benchmarks reported for this measure in MY2022

#### D-150. Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS) (Note that a lower score is better for this measure)









## D-151. Appropriate Treatment for Upper Respiratory Infection (URI), 3 Months-17 Years

<30 Patients

Not Reported







Great Rivers		96.1% 7,584	
Greater Columbia		95.9% 21,383	
King	King County Total	97.6% 16,983	 
	Seattle	97.7% 2,942	
	East King	97.3% 2,439	 
	South King	97.7% 11,522	
North Central		96.4% 7,249	
North Sound		96.3% 14,818	
Pierce		97.3% 14,333	
Salish		97.0% 3,176	
Southwest		98.0% 6,282	 
Spokane		96.5% 14,499	
Thurston -		96.7% 5,284	

<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-152. Appropriate Treatment for Upper Respiratory Infection (URI), 18-64 Years







Great Rivers		91.5% 2,293	
Greater Columbia		93.2% 6,284	
King	King County Total	94.7% 6,076	
	Seattle	94.8% 1,724	
	East King	94.9% 954	-
	South King	94.6% 3,381	
North Central		93.6% 1,786	
North Sound		93.3% 4,952	
Pierce		92.7% 4,363	
Salish		94.4% 1,639	
Southwest		94.1% 2,193	
Spokane		92.5% 6,228	
Thurston - Mason		92.9% 1,961	

<sup>\* \* \*</sup> Data suppressed due to small sample size.


## D-153. Appropriate Treatment for Upper Respiratory Infection (URI), Total

Not Reported






<30 Patients



Great Rivers		95.0% 9,879	 
Greater Columbia		95.3% 27,673	
King	King County Total	96.9% 23,083	 
	Seattle	96.6% 4,674	 
	East King	96.6% 3,395	I I I
	South King	97.0% 14,917	 
North Central		95.9% 9,036	 
North Sound		95.5% 19,778	
Pierce		96.2% 18,701	I I: I:
Salish		96.1% 4,815	 
Southwest		97.0% 8,475	 
Spokane		95.3% 20,733	II I
Thurston - Mason		95.7% 7,246	1: 1: 1:


<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-154. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB), 3 Months-17 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-155. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB), 18-64 Years









Appendix D

#### D-156. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB), Total

<30 Patients

Not Reported






I National 50th

Percentile

Statewide

Weighted Rate





<sup>\* \* \*</sup> Data suppressed due to small sample size.


**Bar Chart Legend:** 

Confidence

Interval


Percentile

#### D-157. Use of Imaging Studies for Low Back Pain (LBP), 18-64 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.

# D-158. Use of Imaging Studies for Low Back Pain (LBP), 65-75 Years





Bar Chart Legend:			
Confidence Interval	Statewide Weighted Rate	National 50th Percentile	National 75th Percentile
	i e.g.itea itate		

Great		* * *	11
Rivers		4	
Greater		* * *	1
Columbia		9	
	King		<u> </u>
King	County Total	# * * * * 9  Ging	
	Seattle		
	East King		
	South King		
North		***	
Central		1	
North		***	
Sound		16	
		* * *	
Pierce		14	
Salish			
Jansh		1	
Southwest		* * *	
Southwest		10	
Snokono		* * *	
Spokane		6	
Thurston -		***	

<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health

D-158.


Appendix D

#### D-159. Use of Opioids at High Dosage (HDO) (Note that a lower score is better for this measure)











#### D-160. Use of Opioids from Multiple Prescribers (UOP) (Note that a lower score is better for this measure)











#### D-161. Use of Opioids from Multiple Pharmacies (UOP) (Note that a lower score is better for this measure)











#### D-162. Use of Opioids from Multiple Prescribers and Multiple Pharmacies (UOP) (Note that a lower score is better for this measure)










#### D-163. Risk of Continued Opioid Use (COU), At least 15 days, 18-64 Years (Note that a lower score is better for this measure)











#### D-164. Risk of Continued Opioid Use (COU), At least 15 days, Total (Note that a lower score is better for this measure)










#### D-165. Risk of Continued Opioid Use (COU), At least 30 days, 18-64 Years (Note that a lower score is better for this measure)











#### D-166. Risk of Continued Opioid Use (COU), At least 30 days, Total (Note that a lower score is better for this measure)










#### D-167. Adults' Access to Preventive/Ambulatory Health Services (AAP), 20-44 Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-168. Adults' Access to Preventive/Ambulatory Health Services (AAP), 45-64 Years





Bar Chart Legend:			
Confidence	Statewide	National 50th	National 75th
Interval	Weighted Rate	Percentile	Percentile

Great Rivers		72.6% 15,274	c	
Greater Columbia		78.7% 25,531		
King	King County Total	73.5% 61,099	,	
	Seattle	72.6% 23,797	·	
	East King	72.9% 9,766	c	
	South King	74.4% 27,524		
North Central		78.8% 10,537		
North Sound		74.9% 37,941		
Pierce		72.4% 29,531	6	
Salish		74.8% 13,119		
Southwest		72.3% 16,768	,	
Spokane		77.1% 26,870		Е
Thurston - Mason		73.1% 12,036	·	

Appendix D


<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-169. Adults' Access to Preventive/Ambulatory Health Services (AAP), 65+ Years









<sup>\* \* \*</sup> Data suppressed due to small sample size.

Comagine Health


D-169.

#### D-170. Adults' Access to Preventive/Ambulatory Health Services (AAP), Total












<sup>\* \* \*</sup> Data suppressed due to small sample size.


#### D-171. Initiation and Engagement of Substance Use Disorder Treatment (IET), Initiation of SUD Treatment, 13-17 years





### D-172. Initiation and Engagement of Substance Use Disorder Treatment (IET), Engagement of SUD Treatment, 13-17 years






#### D-173. Initiation and Engagement of Substance Use Disorder Treatment (IET), Initiation of SUD Treatment, 18-64 Years

Great

**Rivers** 







53.2% 3,171

## **Bar Chart Legend:**

Confidence Interval Statewide Weighted Rate National 50th Percentile


National 75th Percentile

#### D-174. Initiation and Engagement of Substance Use Disorder Treatment (IET), Engagement of SUD Treatment, 18-64 Years









\* \* \* Data suppressed due to small sample size.


D-174.

#### D-175. Initiation and Engagement of Substance Use Disorder Treatment (IET), Initiation of SUD Treatment, Total










#### D-176. Initiation and Engagement of Substance Use Disorder Treatment (IET), Engagement of SUD Treatment, Total










## D-177. Prenatal and Postpartum Care (PPC), Timeliness of Prenatal Care










<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-178. Prenatal and Postpartum Care (PPC), Postpartum Care


Not Reported




<30 Patients








#### D-179. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP), 1-11 Years






**Bar Chart Legend:** 


Confidence Interval

Statewide Weighted Rate I National 50th Percentile

National 75th Percentile

## D-180. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP), 12-17 Years






#### D-181. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP), Total










#### D-182. Well-Child Visits in the First 30 Months of Life (W30), 0-15 Months










<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-183. Well-Child Visits in the First 30 Months of Life (W30), 15-30 Months











<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-184. Child and Adolescent Well-Care Visit (WCV), 3-11 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-185. Child and Adolescent Well-Care Visit (WCV), 12-17 Years


Not Reported





<30 Patients






<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-186. Child and Adolescent Well-Care Visit (WCV), 18-21 Years










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-187. Child and Adolescent Well-Care Visit (WCV), Total











<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-188. Antibiotic Utilization for Respiratory Conditions (AXR), 3 Months-17 Years











<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-189. Antibiotic Utilization for Respiratory Conditions (AXR), 18-64 Years











<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-190. Antibiotic Utilization for Respiratory Conditions (AXR), 65+ Years










\* \* \* Data suppressed due to small sample size.

#### D-191. Antibiotic Utilization for Respiratory Conditions (AXR), Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.


#### D-192. Plan All-Cause Readmissions (PCR), Observed Rate, Total (Note that a lower score is better for this measure)





<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-193. Depression Screening and Follow-Up for Adolescents and Adults (DSF-E), Depression Screening, Total








Great Rivers		0.2% 44,678	ŀ	
Greater Columbia		0.5% 119,324	E	
King	King County Total	0.7% 201,826	ı	
	Seattle	0.7% 67,423	·	
	East King	0.7% 29,119	_	
	South King	0.7% 105,261	С	
North Central		0.4% 42,353	-	
North Sound		0.9% 128,982	C	
Pierce		0.7% 105,271	C	
Salish		0.5% 36,831		
Southwest		0.4% 61,303	C	
Spokane		5.1% 93,993		-
Thurston - Mason		0.3% 38,223	c.	

<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-194. Depression Screening and Follow-Up for Adolescents and Adults (DSF-E), Follow-Up on Positive Screen, Total






<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

Appendix D

### D-195. Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E), Assessment Period 1, Total









(= = ,	,		,	
Great Rivers		0.4% 3,397	_	
Greater Columbia		1.4% 6,805		
King	King County Total	1.1% 11,517	_	
	Seattle	0.8% 4,813	_	
	East King	1.3% 1,765		
	South King	1.4% 4,937		
North Central		0.6% 3,159		
North Sound		2.5% 8,367		
Pierce		0.5% 6,135	_	
Salish		0.3% 2,677	_	
Southwest		1.0% 3,761		
Spokane		8.1% 6,890		_
Thurston - Mason		0.6% 2,893		
* * * Data suppressed due to small sample size.				

<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-196. Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E), Assessment Period 2, Total





<sup>\* \* \*</sup> Data suppressed due to small sample size.

There are no national benchmarks reported for this measure in MY2022

**Bar Chart Legend:** 

Confidence Interval

Statewide Weighted Rate I National 50th Percentile

National 75th Percentile

Comagine Health

D-196.


Appendix D

### D-197. Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E), Assessment Period 3, Total










<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-198. Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E), Total, Total







Great Rivers		0.6% 9,886	-	
Greater Columbia		2.5% 19,555	-	
King	King County Total	2.9% 32,691	-	
	Seattle	2.4% 13,641	-	
	East King	3.4% 5,141	_	
	South King	3.2% 13,904		
North Central		1.9% 9,046		
North Sound		4.6% 24,638		_
Pierce		2.7% 17,843	-	
Salish		0.9% 7,552	-	
Southwest		2.9% 10,994	-	
Spokane		10.8% 19,602		-
Thurston - Mason		1.2% 8,203	-	

<sup>\* \* \*</sup> Data suppressed due to small sample size.

## D-199. Depression Remission or Response for Adolescents and Adults (DRR-E), Follow-Up on PHQ-9, Total





<sup>\* \* \*</sup> Data suppressed due to small sample size.

#### D-200. Depression Remission or Response for Adolescents and Adults (DRR-E), Depression Remission, Total





\* \* \* Data suppressed due to small sample size.


# D-201. Depression Remission or Response for Adolescents and Adults (DRR-E), Depression Response, Total



Great Rivers		* * * 1		
Greater Columbia		13.0% 54		
King	King County Total	* * * 24		
	Seattle	* * * 11		
	East King	* * *		
	South King	* * * 9		
North Central		* * * 7		
North Sound		* * * 13		
Pierce		* * *		
Salish		* * * 1		
Southwest		* * * 10		
Spokane		11.3% 504	_	
Thurston - Mason		* * * 1		
* * * Data suppressed due to small sample size.				

D-201.

### D-202. Unhealthy Alcohol Use Screening and Follow-Up (ASF-E), Unhealthy Alcohol Use Screening, Total





Bar Chart Legend:			
Confidence	Statewide	National 50th	National 75th
Interval	Weighted Rate	Percentile	Percentile

Great Rivers		0.0% 41,833	
Greater Columbia		0.0% 97,328	
King	King County Total	0.0% 182,893	
	Seattle	0.0% 67,377	
	East King	0.0% 26,720	
	South King	0.0% 88,773	
North Central		0.0% 34,950	
North Sound		0.0% 116,129	
Pierce		0.0% 95,140	
Salish		0.0% 36,150	
Southwest		0.0% 53,852	
Spokane		0.0% 87,875	
Thurston - Mason		0.0% 37,063	
* * * Data su	nnressed due	to small sample size.	

<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-203. Adult Immunization Status (AIS-E), Influenza


Not Reported



<30 Patients








<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-204. Adult Immunization Status (AIS-E), Td/Tdap









<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-205. Adult Immunization Status (AIS-E), Zoster


Not Reported



<30 Patients








<sup>\* \* \*</sup> Data suppressed due to small sample size.

### D-206. Prenatal Depression Screening and Follow-Up (PND-E), Depression Screening











\* \* \* Data suppressed due to small sample size.


### D-207. Postpartum Depression Screening and Follow-Up (PDS-E), Depression Screening

<30 Patients









0.0% 1,233

\* \* \* Data suppressed due to small sample size.

Great

**Rivers** 

**Bar Chart Legend:** 

Not Reported

Confidence Interval

Statewide Weighted Rate I National 50th Percentile

National 75th Percentile